| Autores |
Ibanez-Navarro, Marta , Fernandez, Adrian , Escudero, Adela , Esteso, Gloria , CAMPOS SILVA, CARMEN, Navarro-Aguadero, Miguel Angel , Leivas, Alejandra , Caracuel, Beatriz Ruz , Rodriguez-Antolin, Carlos , Ortiz, Alejandra , Navarro-Zapata, Alfonso , Mestre-Duran, Carmen , Izquierdo, Manuel , Balaguer-Perez, Maria , Ferreras, Cristina , Martinez-Lopez, Joaquin , Vales-Gomez, Mar , Perez-Martinez, Antonio , Fernandez, Lucia |
| Abstract |
Introduction Refractory/relapsed pediatric acute leukemia are still clinically challenging and new therapeutic strategies are needed. Interactions between Natural Killer Group 2D (NKG2D) receptor, expressed in cytotoxic immune cells, and its ligands (NKG2DL), which are upregulated in leukemic blasts, are important for anti-leukemia immunosurveillance. Nevertheless, leukemia cells may develop immunoescape strategies as NKG2DL shedding and/or downregulation.Methods In this report, we analyzed the anti-leukemia activity of NKG2D chimeric antigen receptor (CAR) redirected memory (CD45RA-) T cells in vitro and in a murine model of T-cell acute lymphoblastic leukemia (T-ALL). We also explored in vitro how soluble NKG2DL (sNKG2DL) affected NKG2D-CAR T cells\' cytotoxicity and the impact of NKG2D-CAR T cells on Jurkat cells gene expression and in vivo functionality.Results In vitro, we found NKG2D-CAR T cells targeted leukemia cells and showed resistance to the immunosuppressive effects exerted by sNKG2DL. In vivo, NKG2D-CAR T cells controlled T cell leukemia burden and increased survival of the treated mice but failed to cure the animals. After CAR T cell treatment, Jurkat cells upregulated genes related to proliferation, survival and stemness, and in vivo, they exhibited functional properties of leukemia initiating cells.Discussion The data here presented suggest, that, in combination with other therapeutic approaches, NKG2D-CAR T cells could be a novel treatment for pediatric T-ALL. |
Gestionar cookies